| 1 |
33802464 | Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients. | 2021 Mar 3 |
1 |
| 2 |
33237899 | In silico prediction of ARB resistance: A first step in creating personalized ARB therapy. | 2020 Nov |
2 |
| 3 |
28871467 | Epigallocatechin gallate protects against homocysteine-induced vascular smooth muscle cell proliferation. | 2018 Feb |
1 |
| 4 |
29115506 | Angiotensin II induces monocyte chemoattractant protein‑1 expression by increasing reactive oxygen species‑mediated activation of the nuclear factor‑κB signaling pathway in osteoblasts. | 2018 Jan |
1 |
| 5 |
30039424 | Angiotensin II Type 1 Receptor Homology Models: A Comparison Between In Silico and the Crystal Structures. | 2018 |
1 |
| 6 |
28608026 | Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. | 2017 Sep |
1 |
| 7 |
28676728 | [Olmesartan-associated enteropathy: attention to an emerging iatrogenic phenomenon]. | 2017 Aug 31 |
1 |
| 8 |
27152091 | The effect of high glucose on the inhibitory action of C21, a selective AT2R agonist, of LPS-stimulated tissue factor expression in human mononuclear cells. | 2016 |
1 |
| 9 |
25287898 | Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. | 2015 Mar |
2 |
| 10 |
25820021 | Organic Anion Transporter 4-Mediated Transport of Olmesartan at Basal Plasma Membrane of Human Placental Barrier. | 2015 Sep |
1 |
| 11 |
26420482 | Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor. | 2015 Dec 4 |
2 |
| 12 |
24875271 | An efficient synthetic method and theoretical calculations of olmesartan methyl ether: study of biological function of AT1 antagonism. | 2014 |
1 |
| 13 |
24946142 | The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan. | 2014 Oct |
2 |
| 14 |
23154587 | The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. | 2013 Mar |
2 |
| 15 |
23389452 | Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. | 2013 Apr 15 |
1 |
| 16 |
24070321 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? | 2013 Nov |
1 |
| 17 |
21843501 | Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers. | 2011 Dec |
1 |
| 18 |
20353766 | Angiotensin II type 1 receptor blockers prevent tumor necrosis factor-alpha-mediated endothelial nitric oxide synthase reduction and superoxide production in human umbilical vein endothelial cells. | 2010 Jun 25 |
1 |
| 19 |
20374187 | Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan. | 2010 Jan |
1 |
| 20 |
20402577 | The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke. | 2010 May |
1 |
| 21 |
20703229 | The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. | 2010 Nov |
1 |
| 22 |
21142262 | Olmesartan medoxomil: in children and adolescents with hypertension. | 2010 Dec 24 |
1 |
| 23 |
19651759 | Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. | 2009 Sep |
2 |
| 24 |
19689219 | Olmesartan medoxomil: recent clinical and experimental acquisitions. | 2009 Sep |
1 |
| 25 |
19891533 | Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients. | 2009 Dec |
1 |
| 26 |
18300871 | Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. | 2008 Mar |
1 |
| 27 |
18375832 | Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. | 2008 May |
1 |
| 28 |
17554345 | Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. | 2007 Sep |
2 |
| 29 |
17608670 | New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. | 2007 Dec |
2 |
| 30 |
16690611 | Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. | 2006 Jul 14 |
7 |
| 31 |
17192125 | Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence. | 2006 |
1 |
| 32 |
15698454 | Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. | 2005 Mar |
1 |
| 33 |
15291377 | Clinical efficacy and tolerability of olmesartan. | 2004 |
1 |
| 34 |
14668930 | Olmesartan, an AT1-selective antihypertensive agent. | 2003 Oct |
1 |
| 35 |
11967728 | The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. | 2002 May |
2 |
| 36 |
12076183 | Olmesartan medoxomil. | 2002 |
1 |
| 37 |
12239236 | Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. | 2002 Oct |
1 |